CommentaryJournal of Pharmacology and PharmacotherapeuticsVol. 4 | Issue 3 | 2013 | pp. 174–175Open access
The metabolic syndrome and schizophrenia: A comorbidity or an association?
Published in Journal of Pharmacology and Pharmacotherapeutics
Copyright: © 2013 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2013
How to cite
(2013). The metabolic syndrome and schizophrenia: A comorbidity or an association? Journal of Pharmacology and Pharmacotherapeutics, 4(3), 174–175.
Abstract
Individuals with schizophrenia have 2-3 times higher rates of mortality than the general population. Causes of excessive mortality are increased suicide rates and mortality of natural causes such as cardiovascular events.[1] During the last two decades, there has been an increase in the schizophrenia literature discussing the high prevalence of type II diabetes mellitus and pre‑diabetic states such as the metabolic syndrome with a consistent pattern of increased metabolic syndrome prevalence in patients suffering from chronic schizophrenia.[2] Patients suffering from schizophrenia seem to be more prone to have an abdominal obesity, an excess of circulating cortisol as a consequence of their central obesity, and an increased risk of developing insulin resistance. In addition, their reaction to continuous stress hyper‑activates their hypothalamo‑pituitary‑adrenal axis. Moreover, some genetic features might be commonly shared by both schizophrenia and metabolic syndrome. Nevertheless, the lifestyle of patients with schizophrenia is accompanied with risk factors that may increase the risk of development of a metabolic syndrome or aggravate its evolution. Those lifestyle components are excessive sedentarism, excessive smoking, low socio‑economic status, low adherence to medical care, etc
Keywords
Subject
Article metadata
| Title | The metabolic syndrome and schizophrenia: A comorbidity or an association? |
|---|---|
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 4, Issue 3 (2013) |
Also in this issue
- Baldness, a new marker for coronary heart disease riskpp. 223–224
- Improving quality of medical education in India: The need to value and recognize academic scholarshippp. 171–173
- Metabolic syndrome in schizophrenia: Differences between antipsychotic‑naïve and treated patientspp. 176–176
- N-acetyl cysteine in clomiphene citrate resistant polycystic ovary syndrome: A review of reported outcomespp. 187–188
- Neuroprotective role of naringenin on carbaryl induced neurotoxicity in mouse neuroblastoma cellspp. 192–197
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026